Micro RNAs and their significance in the immune response
Authors:
M. Škoda 1; P. Novota 1; M. Remáková 1; M. Faustová 1; J. Vencovský 2
Authors‘ workplace:
Laboratoř molekulární biologie a imunogenetiky, 2Vědeckovýzkumné centrum, Revmatologický ústav Praha
1
Published in:
Čes. Revmatol., 19, 2011, No. 2, p. 56-64.
Category:
Reviews
Overview
Micro RNAs (miRNAs) are a group of short, approximately 22nt long, single-stranded, endogenous and evolutionarily conserved non-coding RNAs. These molecules postranscriptionally regulate the expression of structural genes. By a mechanism termed RNA interference (RNAi) they modulate stability and translational efficiency of target messenger RNAs and thus the intracellular protein levels. MiRNAs can be found in various species, they make up 1–2% of eukaryotic genomes, and regulate expression of about one-third of protein-coding genes. MiRNAs participate in regulation of key biological processes (cell growth, differentiation, proliferation, and apoptosis). Recent findings highlight the crucial importance of miRNAs in development, homeostasis and function of innate and adaptive immunity. Deregulation of miRNA expression is involved in pathogenesis of malignancies, heart diseases, neurodegenerative and inflammatory autoimmune disorders and infections. In systemic autoimmune diseases, miRNAs play a key role in the regulation of major pathogenic molecules (TNFα), central signaling pathways (IFN type I) and critical immunoregulatory cells (regulatory T cells). MiRNA molecules have a considerable potential as a new class of therapeutic targets and diagnostic biomarkers. This article gives a brief overview of miRNA molecules, their role in the immune response and their relation to systemic autoimmune diseases.
Key words:
epigenetic modifications, micro RNA, RNA interference, immune response, systemic autoimmune diseases
Sources
1. Strietholt S, Maurer B, Peters MA, Pap T, Gay S. Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther 2008; 10: 219.
2. Sedivy, JM, Banumathy G, Adams PD. Aging by epigenetics - a consequence of chromatin damage? Exp Cell Res 2008; 314: 1909-17.
3. Yung RL, Julius A. Epigenetics, aging, and autoimmunity. Autoimmunity 2008; 41: 329-335.
4. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet 2009; 10: 94-108.
5. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843–854.
6. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403: 901–906.
7. Rajewsky N, Socci ND. Computational identification of microRNA targets, Dev Biol 2004; 267: 529-35.
8. Duroux-Richard I, Presumey J, Courties G, Gay S, Gordeladze J, Jorgensen C, Kyburz D, Apparailly F. MicroRNAs as new player in rheumatoid arthritis. Joint Bone Spine. In press 2010.
9. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007; 8: 166.
10. Furer V, Greenberg JD, Attur M, Abramson SB, Pillinger MH, The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin Immunol 2010; 136: 1-15.
11. Luo X, Tsai LM, Shen N, Yu D. Evidence for microRNA-mediated regulation in rheumatic diseases. Ann Rheum Dis 2010; 69 (Suppl 1): i30-36.
12. Kim, VN, Nam JW. Genomics of microRNA. Trends Genet 2006; 22: 165-73.
13. Friard O, Re A, Taverna D, De Bortoli M, Corá D. CircuitsDB: a database of mixed microRNA/transcription factor feed-forward regulatory circuits in human and mouse. BMC Bioinformatics 2010; 11: 435.
14. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115: 209-16.
15. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115:199-208.
16. Weil D. GW bodies and stress granules, two cytoplasmic structures for mRNA degradation and storage in mammalian cells. J Soc Biol 2007; 201: 349-58.
17. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC. Mammalian mirtron genes. MolCell 2007 Oct 26; 28: 328-36.
18. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-4.
19. Sonkoly E, Pivarcsi A. Advances in microRNAs: implications for immunity and inflammatory diseases. J Cell Mol Med 2009; 13:24-38.
20. Chen CZ, Li L, Lodish HF, Bartel DP, MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-6.
21. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P, Klein LO, Davis MM, Chen CZ. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007; 129: 147-61.
22. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006; 103: 7024-9.
23. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ, Dougan G, Turner M, Bradley A. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316: 608-11.
24. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, Yancopoulos G, Rao A, Rajewsky K. Regulation of the germinal center response by microRNA-155. Science 2007; 316: 604-8.
25. Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A, Bradley A, Smith KG, Rada C, Enright AJ, Toellner KM, Maclennan IC, Turner M. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007; 27: 847-59.
26. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-14.
27. Fontana L, Pelosi E, Greco P, Racanicchi S, Testa U, Liuzzi F, Croce CM, Brunetti E, Grignani F, Peschle C. MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol 2007; 9: 775-87.
28. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely Proc Natl Acad Sci U S A. 2007; 104: 7080-5.
29. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP, Rajewsky K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007; 131: 146-59.
30. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, Fleming MD, Camargo FD. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008; 451: 1125-9.
31. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006; 103: 12481-6.
32. Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, Lindsay MA. Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol 2008; 180: 5689-98.
33. Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 2009; 183: 2150-8.
34. Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, Pierre P. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A. 2009; 106: 2735-40.
35. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007; 179: 5082-9.
36. Wu H, Neilson JR, Kumar P, Manocha M, Shankar P, Sharp PA, Manjunath N. miRNA profiling of naēve, effector and memory CD8 T cells. PLoS One. 2007; 2: e1020.
37. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P, Klein LO, Davis MM, Chen CZ. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007; 129: 147-61.
38. Lu LF, Liston A. MicroRNA in the immune system, microRNA as an immune system. Immunology 2009; 127:291-8.
39. Muljo SA, Ansel KM, Kanellopoulou C, Livingston DM, Rao A, Rajewsky K. Aberrant T cell differentiation in the absence of Dicer. J Exp Med 2005; 202: 261-9.
40. Liston A, Lu LF, O’Carroll D, Tarakhovsky A, Rudensky AY. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med 2008; 205: 1993–2004.
41. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 2008; 205: 1983-91.
42. Cobb BS, Hertweck A, Smith J, O’Connor E, Graf D, Cook T, Smale ST, Sakaguchi S, Livesey FJ, Fisher AG, Merkenschlager M. A role for Dicer in immune regulation. J Exp Med 2006; 203: 2519-27.
43. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32: 189-94.
44. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 2005; 120: 623-34.
45. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100: 2610-5.
46. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, Chen S, Shen N. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60:1065-75.
47. Gregersen PK, Lee HS, Batliwalla F, Begovich AB. PTPN22: setting thresholds for autoimmunity. Semin Immunol 2006; 18: 214-23.
48. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet 1998; 43: 2-8.
49. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2000; 2: 59-64.
50. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-14.
51. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM, Yu D, Domaschenz H, Whittle B, Lambe T, Roberts IS, Copley RR, Bell JI, Cornall RJ, Goodnow CC. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. re. 2005; 435: 452-8.
52. Yu D, Tan AH, Hu X, Athanasopoulos V, Simpson N, Silva DG, Hutloff A, Giles KM, Leedman PJ, Lam KP, Goodnow CC, Vinuesa CG. Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA. Nature 2007; 450: 299-303.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2011 Issue 2
Most read in this issue
- Treatment with biological drugs in special situations (pregnancy, lactation, vaccination and surgery)
- Extraarticular manifestations of rheumatic diseases and the possibilities of their alleviation by biological therapy
- Biological therapy of rheumatoid arthritis and the risk of tumorous diseases
- Occurrence of infections under treatment with TNF alpha antagonists in ATTRA registry